VC-backed Xagenic receives project funding from Genome Canada
Molecular diagnostics company Xagenic Inc has secured $6 million from Genome Canada for a project being done in partnership with the University of Toronto. The project, which is supported by a matching grant from the Ontario Ministry of Research and Innovation, will develop lower-cost technology for Hepatitis C testing. In July, the Toronto-based Xagenic announced the $25.5 million second close of its Series B financing round. Venture capital firms investing in the round included BDC Capital, CTI Life Sciences Fund, Domain Associates and Ontario Capital Growth Corp.
15 October 2014•3 mins read
